1. Search Result
Search Result
Results for "

BNCT

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-142041

    BSH

    Biochemical Assay Reagents Cancer
    Borocaptate sodium is a boron-containing compound that can be used as a therapeutic agent in boron neutron capture therapy (BNCT), exhibiting anticancer activity .
    Borocaptate sodium
  • HY-W087830

    L-BPA

    Biochemical Assay Reagents Cancer
    L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
    L-p-Boronophenylalanine
  • HY-114376

    BSH-10B12

    Isotope-Labeled Compounds Biochemical Assay Reagents Cancer
    Borocaptate-10B12 (BSH-10B12) sodium is a boron-10 labeled Borocaptate (HY-142041). Borocaptate sodium is a boron-containing compound that can be used as a therapeutic agent in boron neutron capture therapy (BNCT), exhibiting anticancer activity .
    Borocaptate-10B12 sodium
  • HY-172699

    Liposome LDLR Cancer
    DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .
    DSPE-PEG2000-ANG
  • HY-183513

    FAP Cancer
    L-Ala-BPA is a boron delivery agent. L-Ala-BPA is transported into tumor cells via PEPT1/2 and LAT-1 (SLC7A5) pathways and is rapidly cleaved systemically by endogenous proteases including FAP to yield L-BPA (HY-W087830). L-Ala-BPA shows antitumor activity and can be used for the research of Boron Neutron Capture Therapy (BNCT) .
    L-Ala-BPA
  • HY-19938

    Biochemical Assay Reagents Cancer
    MTL-005 is a boron-containing radiosensitizer used in Boron Neutron Capture Therapy (BNCT). MTL-005 enriches the boron-10 isotope in tumor tissues, causing nuclear fission under thermal neutron irradiation, releasing high linear energy transfer (LET) α particles and lithium ions, which selectively destroy tumor cells while minimizing damage to surrounding normal tissues. MTL-005 significantly controlls the tumor progression in the SCCVII squamous cell carcinoma mouse model and prolonged the survival of the mice. MTL-005 can be used to study solid tumors such as head and neck cancer.
    MTL-005
  • HY-183596

    Drug Intermediate Cancer
    L-His-BPA is a prodrug of L-p-Boronophenylalanine (L-BPA) (HY-W087830), formed by the peptide bond linkage of L-histidine (L-His) (HY-N0832) and L-BPA. L-His-BPA is rapidly cleaved by endogenous proteases to de novo release L-BPA in the systemic circulation. When used in combination with neutron irradiation, L-His-BPA induces complete and durable tumor regression, elicits cancer vaccine responses, and produces abscopal inhibitory effects on unirradiated distant tumors. L-His-BPA can be used in studies of boron neutron capture therapy (BNCT) for relapsed/advanced solid tumors .
    L-His-BPA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: